Evidence map›Paper›PMID 40660400›Full record

ReviewBiomarker research2025

T cells in cancer: mechanistic insights and therapeutic advances.

Jingjing Pu, Ting Liu, Yi Zhou, Mengping Chen, Xuehang Fu, Yike Wan, Junying Wang, Binzhen Chen, Amit Sharma, Veronika Lukacs-Kornek and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomarker research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Diagnostics (Basel, Switzerland) · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingjing Pu *Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Ting Liu *Department of Geriatrics, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Yi Zhou *Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Mengping ChenDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Xuehang FuDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Yike WanDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Junying WangDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Binzhen ChenDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
Amit SharmaDepartment of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, NRW, 53127, Bonn, Germany.
Veronika Lukacs-KornekInstitute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, NRW, 53127, Bonn, Germany. vlukacsk@uni-bonn.de.
Ingo G H Schmidt-WolfDepartment of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, NRW, 53127, Bonn, Germany. ingo.schmidt-wolf@ukbonn.de.
Jian HouDepartment of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China. houjian@medmail.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cells are central players in the fight against cancer, capable of recognizing and destroying tumor cells. However, tumors often find ways to evade this immune response, creating challenges for effective treatment. In this review, we explore how different T cell subsets—including cytotoxic T cells, helper T cells, regulatory T cells, and unconventional T cells—contribute to tumor progression or suppression. We also delve into key mechanisms, such as immune checkpoints and metabolic pathways, that shape T cell behavior in the tumor microenvironment. Advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs), T cell engagers (TCEs), adoptive T cell therapies (ACTs), chimeric antigen receptor (CAR) T cell therapies, and cancer vaccines, have transformed cancer treatment and provided new hope for patients. However, challenges such as treatment resistance, limited efficacy in solid tumors, and therapy-associated toxicities remain significant barriers to broader clinical success. We discuss innovative strategies to tackle these challenges, including combination therapies and next-generation T cell engineering approaches. By connecting the biology of T cells with cutting-edge therapeutic advances, this review aims to inspire progress in the development of more effective and personalized cancer treatments.

Indexed as

Adoptive T cell therapyCancer immunotherapyPrecision treatmentT cellsTumor microenvironment

Identifiers

PMID40660400
PMCPMC12261716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.